- Home
- PRAX vs GGAL Comparison
PRAX vs GGAL Comparison
Compare PRAX & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRAX | GGAL |
|---|---|---|
| Founded | 2015 | 1905 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | GGAL |
|---|---|---|
| Price | $332.84 | $47.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $519.60 | $67.50 |
| AVG Volume (30 Days) | 540.8K | ★ 1.2M |
| Earning Date | 02-19-2026 | 03-07-2023 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.35 |
| Revenue | $7,463,000.00 | ★ $3,630,934,738.00 |
| Revenue This Year | N/A | $12.64 |
| Revenue Next Year | $29,535.93 | $18.04 |
| P/E Ratio | ★ N/A | $15.72 |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $25.89 |
| 52 Week High | $328.60 | $66.24 |
Technical Indicators
Market Signals| Indicator | PRAX | GGAL |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 35.17 |
| Support Level | $302.00 | $48.86 |
| Resistance Level | $328.60 | $52.59 |
| Average True Range (ATR) | 16.93 | 2.37 |
| MACD | -0.13 | -0.64 |
| Stochastic Oscillator | 95.16 | 3.23 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.